Podium to Practice: EHA 2026 – Lymphoma: CNS Prophylaxis in High-Risk LBCL
OR
Studies / Trials Discussed
S249 – HIGH-DOSE METHOTREXATE DOES NOT REDUCE RISK OF CNS RELAPSE IN ULTRA HIGH-RISK LARGE B-CELL LYMPHOMA: AN INTERNATIONAL RETROSPECTIVE ANALYSIS OF 1,923 PATIENTS
Co-Chairs
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Merck.
Studies/trials discussed:
S249 – HIGH-DOSE METHOTREXATE DOES NOT REDUCE RISK OF CNS RELAPSE IN ULTRA HIGH-RISK LARGE B-CELL LYMPHOMA: AN INTERNATIONAL RETROSPECTIVE ANALYSIS OF 1,923 PATIENTS
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.